Trial Profile
Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration of 25 mg [14C]-BI 409306 as Oral Solution in Healthy Male Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Osoresnontrine (Primary)
- Indications Alzheimer's disease; Cognition disorders; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 08 Mar 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Jan 2016 Planned End Date changed from 1 Nov 2015 to 1 Mar 2016 as per ClinicalTrials.gov record.
- 25 Jan 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Mar 2016 as per ClinicalTrials.gov record.